BridgeMD
New treatment option for Peripheral T Cell Lymphoma
Official title Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
ClinicalTrials.gov ID: NCT05958719
What this study is testing
What is Chidamide?
Chidamide is an investigational medicine, given as an once-weekly pill taken by mouth, being studied as a potential treatment for peripheral t cell lymphoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is investigating the effectiveness (specifically the objective response rate - ORR) of a new combination therapy called CAMP (chidamide, azacitidine, liposomal mitoxantrone, and prednisone) for previously untreated angioimmunoblastic T-cell lymphoma (AITL). It's a single-arm study comparing CAMP's safety and efficacy to standard treatments.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- people must have histological confirmation of nodal T-follicular helper (TFH) cell lymphoma.
- More than 18 years of age.
- Proper functioning of the major organs: 1) The absolute value of neutrophils (≥1×10\^9/L); 2) platelet count (≥75×10\^9/L); 3) Serum total bilirubin...
- Eastern Cooperative Oncology Group (ECOG) Performance status 0-2.
- LVEF value measured by echocardiography ≥50%.
You likely can't join if
- Patients who have previously received chemotherapy, radiotherapy or other antitumor therapy.
- Patients with central nervous system involvement by lymphoma.
- Patients with uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, serious infectious...
- Pregnant or breastfeeding women.
- Presence of human immunodeficiency virus (HIV) virus infection.
- Previous history of other malignant tumors, unless the disease has been cured for 5 years or more. The following cured tumors are excluded:
See the full eligibility criteria
- people must have histological confirmation of nodal T-follicular helper (TFH) cell lymphoma.
- More than 18 years of age.
- Proper functioning of the major organs: 1) The absolute value of neutrophils (≥1×10\^9/L); 2) platelet count (≥75×10\^9/L); 3) Serum total bilirubin ≤ 1.5 times ULN; 4) Aspartate Aminotransferase (AST), Alanine...
- Eastern Cooperative Oncology Group (ECOG) Performance status 0-2.
- LVEF value measured by echocardiography ≥50%.
- Life expectancy \> 3 months.
- Patients who have previously received chemotherapy, radiotherapy or other antitumor therapy.
- Patients with central nervous system involvement by lymphoma.
- Patients with uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, serious infectious diseases and other diseases.
- Pregnant or breastfeeding women.
- Presence of human immunodeficiency virus (HIV) virus infection.
- Previous history of other malignant tumors, unless the disease has been cured for 5 years or more. The following cured tumors are excluded:
- Basal cell carcinoma of the skin, squamous cell carcinoma of the skin and related localized non-melanoma skin cancers;
- Carcinoma in situ of the cervix
The study team makes the final eligibility decision.
Where it's taking place
- Tianjin, Tianjin Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tianjin, Tianjin Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.